Quarter Comparison
Revenue
Gross Margin
Net Margin
EPS (Diluted)
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 elut-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ● Funded through launch
EX-99.1 2 elut-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ● Funded through launch: secured up to $26 million of capital without an equity offering ● The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk ● The demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committee ● On track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027 ● GAITHERSBURG, Md., August 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix...
Source
Exhibit EX-99.1
0001104659-26-095934
Filed August 13, 2026 at 8:15 PM UTC. The figures above are from the audited statements, not from this release.